N-[11C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 192-197

  Moreau, Steven ^a,b   DaSilva, Jean N ^a,b,c   Valdivia, Ana ^a   Fernando, Pasan ^a,b,d  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MDS Inc   (Canada)

Author keywords

Cardiomyocyte; ERK 1 2; Isoproterenol; MTOR; ROCK; adrenergic receptor stimulation

Indexed keywords

BETA ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; HYDROXYFASUDIL; ISOPRENALINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL HYDROXYFASUDIL C 11; RADIOPHARMACEUTICAL AGENT; RHO KINASE; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; N-METHYL-HYDROXYFASUDIL; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; BETA ADRENERGIC STIMULATION; BINDING ASSAY; CELL SIZE; CELL STIMULATION; CELL TRANSFORMATION; CYTOCHEMISTRY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; NEWBORN; NONHUMAN; NUCLEAR SIZE; PHENOTYPE; RAT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CARDIOMEGALY; CELL NUCLEUS; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SPRAGUE DAWLEY RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BIOLOGICAL MARKERS; CARDIOMEGALY; CELL NUCLEUS; CELL NUCLEUS SIZE; ENZYME ACTIVATION; ISOPROTERENOL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; TOR SERINE-THREONINE KINASES;

EID: 84921317445     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.09.008     Document Type: Article

References (28)

1. Beltrami A.P., Urbanek K., Kajstura J., Yan S.M., Finato N., Bussani R., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344(23):1750-1757.
2. Nadal-Ginard B., Kajstura J., Leri A., Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003, 92(2):139-150.
3. Hannan R.D., Jenkins A., Jenkins A.K., Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 2003, 30(8):517-527.
4. Fielitz J., Kim M.S., Shelton J.M., Qi X., Hill J.A., Richardson J.A., et al. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci U S A 2008, 105(8):3059-3063.
5. Chakraborti S., Chakraborti T., Shaw G. beta-adrenergic mechanisms in cardiac diseases: a perspective. Cell Signal 2000, 12(8):499-513.
6. Marian A.J. Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans. J Mol Cell Cardiol 2006, 41(1):11-13.
7. Lezoualc'h F., Metrich M., Hmitou I., Duquesnes N., Morel E. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 2008, 44(4):623-632.
8. Molkentin J.D., Dorn G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001, 63:391-426.
9. Proud C.G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004, 63(3):403-413.
10. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107(12):1664-1670.
11. Manning B.D., Cantley L.C. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003, 28(11):573-576.
12. Denker S.P., Huang D.C., Orlowski J., Furthmayr H., Barber D.L. Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H(+) translocation. Mol Cell 2000, 6(6):1425-1436.
13. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4(6):446-456.
14. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 2001, 69(12):1441-1453.
15. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004, 94(1):46-52.
16. Valdivia A.C., Mason S., Collins J., Buckley K.R., Coletta P., Beanlands R.S., et al. Radiosynthesis of N-[(11)C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs). Appl Radiat Isot 2010, 68(2):325-328.
17. Morisco C., Zebrowski D.C., Vatner D.E., Vatner S.F., Sadoshima J. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol 2001, 33(3):561-573.
18. Ramos K., Acosta D. Prevention by L(-) ascorbic acid of isoproterenol-induced cardiotoxicity in primary cultures of rat myocytes. Toxicology 1983, 26(1):81-90.
19. Ramos K., Combs A.B., Acosta D. Cytotoxicity of isoproterenol to cultured heart cells: effects of antioxidants on modifying membrane damage. Toxicol Appl Pharmacol 1983, 70(2):317-323.
20. Fernando P., Kelly J.F., Balazsi K., Slack R.S., Megeney L.A. Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci U S A 2002, 99(17):11025-11030.
21. Valdivia A.C., Estrada M., Hadizad T., Stewart D.J., Beanlands R.S., Dasilva J.N. A fast, simple, and reproducible automated synthesis of [18F]FPyKYNE-c(RGDyK) for avß3 receptor positron emission tomography imaging. J Label Compd Radiopharm 2011, 55:4.
22. Chang J., Xie M., Shah V.R., Schneider M.D., Entman M.L., Wei L., et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci U S A 2006, 103(39):14495-14500.
23. Gerdes A.M., Liu Z., Zimmer H.G. Changes in nuclear size of cardiac myocytes during the development and progression of hypertrophy in rats. Cardioscience 1994, 5(3):203-208.
24. Lohse M.J., Benovic J.L., Caron M.G., Lefkowitz R.J. Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. J Biol Chem 1990, 265(6):3202-3211.
25. Zheng M., Hou R., Han Q., Xiao R.P. Different regulation of ERK1/2 activation by beta-adrenergic receptor subtypes in adult mouse cardiomyocytes. Heart Lung Circ 2004, 13(2):179-183.
26. Kacimi R., Gerdes A.M. Alterations in G protein and MAP kinase signaling pathways during cardiac remodeling in hypertension and heart failure. Hypertension 2003, 41(4):968-977.
27. Schofield A.V., Bernard O. Rho-associated coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem Mol Biol 2013, 48(4):301-316.
28. Peng F., Wu D., Gao B., Ingram A.J., Zhang B., Chorneyko K., et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008, 57(6):1683-1692.